PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Bannon’s War Room | Episode 2221 | Morning Edition Hour 2 | Recorded October 12, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2220 | Morning Edition Hour 1 | Recorded October 12, 2022 | Video: 48 Minutes 58 Seconds

Show Me

The Democrat Party Establishment Once Again Rolls Over And Shows It’s Ugly Underbelly | “Racist remarks in leaked audio of L.A. council members spark outrage, disgust” | The Los Angeles Times

Show Me

William Shatner: My Trip to Space Filled Me With ‘Overwhelming Sadness’ (EXCLUSIVE) | Variety

Show Me

Could Jupiter’s Icy Moon Harbor Life? | The Atlantic

Show Me

Nightly News Rebroadcast | October 11, 2022 | Video: 26 Minutes 13 Seconds

Show Me

Bannon’s War Room | Episode 2219 | Evening Edition | Recorded October 11, 2022 | Video: 48 Minutes 59 Seconds

Show Me

Cuba: Tactics of repression must not be repeated | Amnesty International

Show Me

Peer Reviewed Study: 94 Percent of Vaccinated Patients With Subsequent Health Issues Have Abnormal Blood | National File

Show Me

Bannon’s War Room | Episode 2218 | Morning Edition Hour 2 | Recorded October 11, 2022 | Video: 48 Minutes 59 Seconds

Show Me

Bannon’s War Room | Episode 2217 | Morning Edition Hour 1 | Recorded October 11, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2216 | Evening Edition | Recorded October 10, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Nightly News Rebroadcast | October 10, 2022 | Video: 25 Minutes 46 Seconds

Show Me

Why Democrats are Switching Sides – Kari Lake | Awaken With JP

Show Me

‘Waking Up the Sheep’: Texas Siblings Sound Alarm on Hospital COVID Treatment Protocols After Death of Mother

Show Me

FDA Approves First COVID Treatment for Young Children Despite Alarming Risks | Epoch Times

Show Me

Minnesota doctor embattled with state board over COVID treatment gets Johnson backing for governor | Just The News

Show Me

Wanton War on Early Covid Treatment | Townhall

Show Me

What You Need to Know About Early At-Home COVID Treatment | Dr. Mercola

Show Me

Joe Rogan’s ‘Emergency Podcast’ Questions YouTube’s Censorship of Content Showing Ivermectin as an Effective COVID Treatment

Show Me

Bannon’s War Room | Episode 2215 | Morning Edition Hour 2 | Recorded October 10, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2214 | Morning Edition Hour 1 | Recorded October 10, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Dr. Paul Marik Speaks About The Silencing of Doctors Who Want to Speak Out About the COVID Vaccines | Video: 48 Minutes 54 Seconds

Show Me

Bannon’s War Room | Episode 2213 | Saturday Edition Hour 2 | Recorded October 8, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Bannon’s War Room | Episode 2212 | Saturday Edition Hour 1 | Recorded October 8, 2022 | Video: 48 Minutes 58 Seconds

Show Me

Ron DeSantis says Biden should get ‘honorary’ drug cartel membership for border policies | New York Post

Show Me

Vancouver’s safe drug-use sites are wrenching to see. California should open them anyway | Los Angeles Times

Show Me

Federal indictment tossed after ex-DEA supervisor says Latinos ‘typically’ supply drugs in Chicago | Chicago Sun-Times

Show Me

Feds find major drug-smuggling tunnel at US-Mexican border | New York Post

Show Me

Homeland Security memo: Drug cartels control human trafficking corridors to Biden border | Just The News

Show Me

China and Mexican Drug Cartels Helped Murder 339,849 Americans and Most Politcians Do Not Care | The Gateway Pundit

Show Me

Horrific moment TV journalist sobs over body of her anti-drug prosecutor husband after he was gunned down on their HONEYMOON in Colombia just hours after she revealed she was pregnant | Daily Mail UK

Show Me

DEA Quietly Removes Narco-Busting Aircraft From Mexico As Drug Overdoses Skyrocket | Daily Caller

Show Me

Texas mom who laced baby’s milk with drugs will only serve probation | New York Post

Show Me

Drug Overdose Deaths Rise Nearly 15% in Joe Biden’s First Year as President | Breitbart

Show Me

Former Honduran President Hernandez Pleads Not Guilty to US Drug Charges

Show Me

Denise Francine ‘Fran’ Boyd Andrews, a drug counselor whose battle with addiction inspired a book and HBO miniseries, dies

Show Me

Utah Was Warned Racial Rationing of COVID Drugs Was Illegal. It Did It Anyway. | The Washington Free Beacon

Show Me

BORDER TOWN USA: Nashville Trio Moved Mexican Cartel Drugs Across Nation | Breitbart

Show Me

Nightly News Rebroadcast | October 7, 2022 | Video: 27 Minutes 06 Seconds

Show Me